Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease
Haixia Su, Sheng Yao, Wenfeng Zhao, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 162

Showing 1-25 of 162 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 420
The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Qing Hu, Yuan Xiong, Guanghao Zhu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 148
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure–Activity Relationship Insights and Evolution Perspectives
Gabriele La Monica, Alessia Bono, Antonino Lauria, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 12500-12534
Open Access | Times Cited: 101
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 82
Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19
Haiyu Xu, Shufen Li, Jiayuan Liu, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 18
Open Access | Times Cited: 81
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19
Hengrui Liu, Sho Iketani, Arie Zask, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 79
Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds
Io Antonopoulou, Eleftheria Sapountzaki, Ulrika Rova, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 1306-1344
Open Access | Times Cited: 70
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li, Yongcheng Song
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115772-115772
Open Access | Times Cited: 52
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
Thales Kronenberger, Stefan Laufer, Thanigaimalai Pillaiyar
Drug Discovery Today (2023) Vol. 28, Iss. 6, pp. 103579-103579
Open Access | Times Cited: 43
Challenges and opportunities of the exotic invasive macroalga Rugulopteryx okamurae (Phaeophyceae, Heterokontophyta)
Félix L. Figueroa, Julia Vega, Noelia Flórez‐Fernández, et al.
Journal of Applied Phycology (2025)
Open Access | Times Cited: 2
Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review
Ridhima Kaul, Pradipta Paul, Sanjay Kumar, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 11069-11069
Open Access | Times Cited: 85
Bioactive natural products in COVID-19 therapy
Zhonglei Wang, Ning Wang, Liyan Yang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 58
Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19
Yi Yang, Meng Zhang, Heng Xue, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 11, pp. 4154-4164
Open Access | Times Cited: 55
Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS‐CoV‐2 Infection and COVID‐19
Arun K. Ghosh, Jennifer L. Mishevich, Andrew D. Mesecar, et al.
ChemMedChem (2022) Vol. 17, Iss. 22
Open Access | Times Cited: 44
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1339-1339
Open Access | Times Cited: 28
SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
Conrad Fischer, Jenson R. Feys
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 80-107
Open Access | Times Cited: 25
The Therapeutic Potential of Natural Dietary Flavonoids against SARS-CoV-2 Infection
Zhonglei Wang, Liyan Yang
Nutrients (2023) Vol. 15, Iss. 15, pp. 3443-3443
Open Access | Times Cited: 25
Structural biology of SARS-CoV-2 Mpro and drug discovery
Yinkai Duan, Haofeng Wang, Zhenghong Yuan, et al.
Current Opinion in Structural Biology (2023) Vol. 82, pp. 102667-102667
Closed Access | Times Cited: 23
Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors
Shenghua Gao, Tianguang Huang, Letian Song, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 2, pp. 581-599
Open Access | Times Cited: 45
A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?
Guillem Macip, Pol Garcia‐Segura, Júlia Mestres‐Truyol, et al.
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 259-259
Open Access | Times Cited: 42
Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity
Mohamed Haddad, Roger Gaudreault, Gabriel Sasseville, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2643-2643
Open Access | Times Cited: 34
Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease Mpro and Papain-like Protease PLpro of SARS-CoV-2
Lucianna Helene Santos, Thales Kronenberger, Renata G. Almeida, et al.
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 24, pp. 6553-6573
Open Access | Times Cited: 34
The expanding repertoire of covalent warheads for drug discovery
Namrashee V. Mehta, Mariam S. Degani
Drug Discovery Today (2023) Vol. 28, Iss. 12, pp. 103799-103799
Closed Access | Times Cited: 21
Natural products as potential lead compounds to develop new antiviral drugs over the past decade
Jing-Han Zhao, Yuewei Wang, Jin Yang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115726-115726
Closed Access | Times Cited: 20
Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19
Nadine Krüger, Thales Kronenberger, Hang Xie, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 190-190
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top